Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
C CarrilesPaula Jiménez-FonsecaManuel Sánchez CánovasP PimentelAlberto Carmona-BayonasTeresa García GarcíaM Carbajales-ÁlvarezAna LozanoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Results suggest reconsidering TAS-102 in patients with ECOG > 0, something that should be investigated in prospective randomized clinical trials.